Skip header and navigation

6 records – page 1 of 1.

Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Updated Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer. However, more data are beginning to elucidate the nuances of these risks depending on patient specific factors.
Limited data indicate that pediatric cancer patients are not at a high level of risk of severe outcomes from COVID-19.
Limited evidence indicates some differences in the course and severity of SARS-CoV-2 infection depending on the type of immunosuppressive therapy a patient receives.
Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer.
Pediatric cancer populations may not be at the same level of risk as adult populations.
There is not enough evidence at this time to determine if there are differences in the course of SARS-CoV-2 infection in patients receiving chemotherapy vs. those who are not aside from outcomes and severity.
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC062201v2 RR Table
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Document Type
Table
Review Code
EOC062201v2 RR Table
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST table)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents

EOC062201v2 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
LAB041601v2 RR
Question Submitted
April 16, 2020
Date Completed
May 19, 2020
Status
5. Updated review
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041601v2 RR
Question Submitted
April 16, 2020
Date Completed
May 19, 2020
Status
5. Updated review
Research Team
Laboratory
Key Findings
Patients with higher and prolonged IgM antibodies are associated with more severe illness, poor recovery, and prolonged viral shedding (some patients may shed virus for more than 30 days).
Patients who respond weakly to IgG have higher viral clearance rate than strong responders.
There were no reports with direct information regarding infectiousness of patients.
Category
Diagnostics
Clinical Presentation
Subject
Transmission
Antibodies
Natural History
Population
All
Cite As
Vanstone, J; Reeder, B; Duncan, V. What is the relationship between antibody development and viral shedding and infectiousness? 2020 May 19; Document no.: LAB041601v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Review History
LAB041601 RR: April 16, 2020
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB040701v2 RR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB040701v2 RR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Key Findings
COVID-19 is primarily transmitted by symptomatic patientsand presymptomatic individuals.·Moderate grade evidence estimates that approximately 20% of COVID-19 transmission may bedue to that from presymptomatic individuals.However, estimates range from 6.4% -47%.·Asymptomatic individuals and environmental contaminationappear to contributelessto disease transmission,with estimated proportionsof 6% and 10%, respectivelyfrom modelling studies
Category
Clinical Presentation
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Asymptomatic
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B; What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? 2020 May 8; Document no.: LAB040701v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST rapid review report)
Similar Reviews
EPM051301 RR
Review History
LAB040701 RR: April 7, 2020
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
The majority of patients (>50%) appear to seroconvert between 8-14 days following the onset of symptoms.
Nearly all patients (>80%) seroconvert >15 days following the onset of symptoms.
The IgM response is detected earlier (median 12 days) than the IgG response (median 14 days).
Seroconversion appears to follow clinical recovery in most cases.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Low grade evidence shows IgG and IgM antibody response correlates with neutralizingantibody titerand viral clearance, which is suggestive of protective humoral immunity inCOVID-19 patients with mild to moderate symptoms.
There is no available evidence with which to estimate the durability of this protective response. However, if the immune response to SARS-CoV-2 resembles that toward SARS-CoV, this protective humoral immunity may persist for several years.
Higher IgG antibody titersand a robustresponse were noted in severe to criticallyill patients and were associated with lower viral clearance and a worse clinical prognosis.
Low grade evidence suggests that convalescent plasma treatment may improve the clinical status of critically ill COVID-19 patients(one case series with only five patients enrolled).
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Duncan, V; Is the IgM or IgG immune response protective? 2020 Apr 11; Document no.: LAB040803 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST rapid review report)
Related Documents
Documents
Less detail

6 records – page 1 of 1.